San Francisco, CA, United States of America

Kathleen Ann Elias

This inventor holds 20 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 6 EPO patents, primarily in Biotechnology. Top assignees: Takeda Pharmaceutical Company Limited, Cytokinetics, Inc., Genentech, Inc.. Active years: 1998-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kathleen Ann Elias. Retrieved from https://idiyas.com/inventor/kathleen-ann-elias

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 4)

% Patents Active = 95.0

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 6.0

ph-index = 7

Forward Citations = 144(Granted Patents)

Location History:

San Francisco, CA (US) (1998 - 2022)
South San Francisco, CA (US) (2008 - 2022)

Company Filing History:

11 out of 1,229

Takeda Pharmaceutical Company Limited

Years Active: 1998-2025

Loading Chart...

Areas of Expertise:

Anti-CD38

Antibodies

Heart Failure

Peptidomimetic

Therapeutics

Compositions

Cell-Cell Interactions

Growth Hormone Secretagogues

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12312411 - Anti-CD38 binding domains (2025-05-27),

2. 12209138 - Anti-CD38 antibodies (2025-01-28),

3. 11434304 - Anti-CD38 antibodies (2022-09-06),

4. 11414496 - Anti-CD38 binding domains (2022-08-16),

5. 10494444 - Anti-CD38 antibodies (2019-12-03),

6. 10336833 - Conjugated anti-CD38 antibodies (2019-07-02),

7. 9790285 - Anti-CD38 antibodies (2017-10-17),

8. 9676869 - Conjugated anti-CD38 antibodies (2017-06-13),

9. 9102744 - Conjugated anti-CD38 antibodies (2015-08-11),

10. 8926969 - Anti-CD38 antibodies (2015-01-06),

11. 8362211 - Anti-CD38 antibodies (2013-01-29),

12. 7605164 - Compositions and methods for treating heart failure (2009-10-20),

13. 7491826 - Compounds, compositions and methods (2009-02-17),

14. 7399866 - Compounds, compositions, and methods (2008-07-15),

15. 7094869 - Low molecular weight peptidomimetic growth hormone secretagogues (2006-08-22),

Title: The Innovative Work of Kathleen Ann Elias in Immunotherapy

Introduction: Kathleen Ann Elias is a notable inventor based in San Francisco, California, whose contributions to the field of immunotherapy are underscored by 19 patents. Her inventive work mainly revolves around the development of anti-CD38 antibodies, establishing her as a significant figure in the pharmaceutical industry.

Latest Patents: Kathleen's latest patents include innovative developments related to anti-CD38 antibodies. These isolated antibodies bind to human CD38 and cynomolgus CD38, which have broad implications in therapeutic and diagnostic applications. The patents disclose not only the antibodies themselves but also the pharmaceutical compositions comprising these antibodies, showcasing potential avenues for treatment.

Career Highlights: Throughout her career, Kathleen has made substantial contributions while working with leading pharmaceutical companies, including Takeda Pharmaceutical Company Limited and Cytokinetics, Inc. Her expertise and groundbreaking research have propelled advancements in the field of antibody therapeutics.

Collaborations: Kathleen has collaborated with esteemed colleagues such as Wouter Korver and Andrew Walling Drake, contributing to a robust exchange of ideas and advancements in immunotherapy. These partnerships have amplified her impact, fostering innovative developments in the sector.

Conclusion: Kathleen Ann Elias exemplifies the spirit of innovation with her extensive portfolio of patents and impactful work in immunotherapy. Her dedication to research and collaboration continues to influence the medical and pharmaceutical landscapes, paving the way for future advancements.

Profile summary based on public USPTO records.